Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)

Celgene1,149 enrolled

Overview

To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter referred to as relapsed or refractory Adult T-cell Leukemia Lymphoma (ATLL)). 1. Planned registration period 3 years 2. Planned surveillance period 4 years and 6 months after a month after the approval for partial changes in the approved items is granted for relapsed or refractory ATLL

Study Type

OBSERVATIONAL

Enrollment

1,149

Conditions

Lymphoma

Interventions

RevlimidDRUG

Revlimid

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- Relapsed or Refractory Adult T-cell Leukemia Lymphoma Exclusion Criteria: * N/A

Locations (1)

ASO KK Iizuka Hospital

Iizuka, Fukuoka, Japan

Outcomes

Primary Outcomes

Adverse Events (AEs)

Number of participants with adverse events

Time frame: Up to approximately 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.